Tarsus bets $450M on Alkeus’ Stargardt drug
To broaden its ophthalmology portfolio, Tarsus Pharmaceuticals is dishing out $450 million upfront to acquire Phase 3 biotech Alkeus Pharmaceuticals, the companies said Thursday morning. It's the latest signal that small- ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.




